ES2286108T3 - Inmunizacion contra carcinomas y sus previas. - Google Patents
Inmunizacion contra carcinomas y sus previas. Download PDFInfo
- Publication number
- ES2286108T3 ES2286108T3 ES01913586T ES01913586T ES2286108T3 ES 2286108 T3 ES2286108 T3 ES 2286108T3 ES 01913586 T ES01913586 T ES 01913586T ES 01913586 T ES01913586 T ES 01913586T ES 2286108 T3 ES2286108 T3 ES 2286108T3
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- carcinomas
- cell cycle
- cells
- cycle regulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000009030 Carcinoma Diseases 0.000 title claims abstract description 27
- 238000002649 immunization Methods 0.000 title claims abstract description 13
- 230000003053 immunization Effects 0.000 title claims abstract description 13
- 239000012634 fragment Substances 0.000 claims abstract description 13
- 101710150974 Regulator of chromosome condensation Proteins 0.000 claims abstract description 10
- 102100039977 Regulator of chromosome condensation Human genes 0.000 claims abstract description 10
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 10
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 10
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 10
- 102000034356 gene-regulatory proteins Human genes 0.000 claims abstract description 5
- 108091006104 gene-regulatory proteins Proteins 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 5
- 230000002163 immunogen Effects 0.000 claims abstract description 3
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 208000019065 cervical carcinoma Diseases 0.000 claims description 4
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 2
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 2
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 abstract description 4
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 abstract 1
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 10
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 9
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- MFVQGXGQRIXBPK-WDSKDSINSA-N Gly-Ala-Glu Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFVQGXGQRIXBPK-WDSKDSINSA-N 0.000 description 2
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 description 2
- JOYFULUKJRJCSX-IUCAKERBSA-N Met-Met-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O JOYFULUKJRJCSX-IUCAKERBSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WECYCNFPGZLOOU-FXQIFTODSA-N Pro-Asn-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O WECYCNFPGZLOOU-FXQIFTODSA-N 0.000 description 2
- FIXILCYTSAUERA-FXQIFTODSA-N Ser-Ala-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FIXILCYTSAUERA-FXQIFTODSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 108010036413 histidylglycine Proteins 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108010036387 trimethionine Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- VUGWHBXPMAHEGZ-SRVKXCTJSA-N Arg-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N VUGWHBXPMAHEGZ-SRVKXCTJSA-N 0.000 description 1
- HXVILZUZXFLVEN-DCAQKATOSA-N Asp-Met-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O HXVILZUZXFLVEN-DCAQKATOSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- MUGLKCQHTUFLGF-WPRPVWTQSA-N Gly-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)CN MUGLKCQHTUFLGF-WPRPVWTQSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- VOEGKUNRHYKYSU-XVYDVKMFSA-N His-Asp-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O VOEGKUNRHYKYSU-XVYDVKMFSA-N 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- LRALLISKBZNSKN-BQBZGAKWSA-N Met-Gly-Ser Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LRALLISKBZNSKN-BQBZGAKWSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 101100185402 Mus musculus Mug1 gene Proteins 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- POQFNPILEQEODH-FXQIFTODSA-N Pro-Ser-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O POQFNPILEQEODH-FXQIFTODSA-N 0.000 description 1
- NIOYDASGXWLHEZ-CIUDSAMLSA-N Ser-Met-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O NIOYDASGXWLHEZ-CIUDSAMLSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- YFOCMOVJBQDBCE-NRPADANISA-N Val-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N YFOCMOVJBQDBCE-NRPADANISA-N 0.000 description 1
- WHVSJHJTMUHYBT-SRVKXCTJSA-N Val-Met-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(=O)O)N WHVSJHJTMUHYBT-SRVKXCTJSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10006033 | 2000-02-10 | ||
| DE10006033A DE10006033B4 (de) | 2000-02-10 | 2000-02-10 | Immunisierung eines Individuums gegen Carcinome und ihre Vorstufen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2286108T3 true ES2286108T3 (es) | 2007-12-01 |
Family
ID=7630548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01913586T Expired - Lifetime ES2286108T3 (es) | 2000-02-10 | 2001-02-07 | Inmunizacion contra carcinomas y sus previas. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20030139334A1 (enExample) |
| EP (1) | EP1253938B1 (enExample) |
| JP (1) | JP4936626B2 (enExample) |
| AT (1) | ATE360439T1 (enExample) |
| AU (1) | AU2001239160A1 (enExample) |
| CA (1) | CA2400007C (enExample) |
| DE (2) | DE10006033B4 (enExample) |
| ES (1) | ES2286108T3 (enExample) |
| WO (1) | WO2001058477A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| PT1041987E (pt) | 1997-12-22 | 2006-07-31 | Euro Celtique Sa | Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona |
| MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
| PT1729730E (pt) | 2004-03-30 | 2009-04-06 | Euro Celtique Sa | Forma de dosagem resistente às violações que compreende um adsorvente e um agente adverso |
| US10279018B2 (en) * | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| CN103293308B (zh) * | 2013-05-24 | 2014-11-26 | 尉军 | 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用 |
| CN111434674B (zh) * | 2018-12-25 | 2024-02-09 | 上海细胞治疗集团有限公司 | 多肽组合物及其在癌症免疫治疗中的用途 |
| CN111848732B (zh) * | 2019-04-30 | 2024-03-12 | 上海细胞治疗集团有限公司 | 多肽组合物及疫苗 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889169A (en) * | 1991-05-16 | 1999-03-30 | Cold Spring Harbor Laboratory | Cell cycle regulatory protein p16 gene |
| AU7015396A (en) * | 1995-09-07 | 1997-03-27 | Health Research Incorporated | Cyclin e variants and use thereof |
| US5723313A (en) * | 1995-09-27 | 1998-03-03 | St. Jude Children's Research Hospital | ARF-p19, a novel regulator of the mammalian cell cycle |
| US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US6287569B1 (en) * | 1997-04-10 | 2001-09-11 | The Regents Of The University Of California | Vaccines with enhanced intracellular processing |
| AU739189B2 (en) * | 1997-07-10 | 2001-10-04 | Mannkind Corporation | A method of inducing a CTL response |
| WO1999019357A2 (en) * | 1997-10-15 | 1999-04-22 | President And Fellows Of Harvard College | Cell regulatory genes, encoded products, and uses related thereto |
| US6066651A (en) | 1997-10-29 | 2000-05-23 | Ortho-Mcneil Pharmaceutical, Inc. | Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders |
| DE19829473C2 (de) * | 1998-07-01 | 2000-08-10 | Magnus Von Knebel Doeberitz Ch | Verfahren zur frühen Diagnose von Carcinomen |
| BR9916831A (pt) * | 1998-12-17 | 2001-11-20 | Cropdesign Nv | Genes do ciclo celular e seu uso |
-
2000
- 2000-02-10 DE DE10006033A patent/DE10006033B4/de not_active Expired - Lifetime
-
2001
- 2001-02-07 WO PCT/DE2001/000470 patent/WO2001058477A2/de not_active Ceased
- 2001-02-07 EP EP01913586A patent/EP1253938B1/de not_active Expired - Lifetime
- 2001-02-07 JP JP2001557585A patent/JP4936626B2/ja not_active Expired - Lifetime
- 2001-02-07 CA CA002400007A patent/CA2400007C/en not_active Expired - Lifetime
- 2001-02-07 US US10/203,206 patent/US20030139334A1/en not_active Abandoned
- 2001-02-07 DE DE50112401T patent/DE50112401D1/de not_active Expired - Lifetime
- 2001-02-07 AT AT01913586T patent/ATE360439T1/de active
- 2001-02-07 ES ES01913586T patent/ES2286108T3/es not_active Expired - Lifetime
- 2001-02-07 AU AU2001239160A patent/AU2001239160A1/en not_active Abandoned
-
2006
- 2006-05-15 US US11/433,386 patent/US7569538B2/en not_active Expired - Lifetime
-
2009
- 2009-07-09 US US12/500,458 patent/US8946171B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8946171B2 (en) | 2015-02-03 |
| JP2003522157A (ja) | 2003-07-22 |
| CA2400007A1 (en) | 2001-08-16 |
| DE10006033B4 (de) | 2005-11-10 |
| DE50112401D1 (de) | 2007-06-06 |
| US20060210591A1 (en) | 2006-09-21 |
| EP1253938B1 (de) | 2007-04-25 |
| WO2001058477A2 (de) | 2001-08-16 |
| JP4936626B2 (ja) | 2012-05-23 |
| AU2001239160A1 (en) | 2001-08-20 |
| ATE360439T1 (de) | 2007-05-15 |
| DE10006033A1 (de) | 2001-08-23 |
| EP1253938A2 (de) | 2002-11-06 |
| US7569538B2 (en) | 2009-08-04 |
| US20110064770A1 (en) | 2011-03-17 |
| US20030139334A1 (en) | 2003-07-24 |
| CA2400007C (en) | 2008-08-26 |
| WO2001058477A3 (de) | 2002-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2378264T3 (es) | Péptido antigénico de unión a HLA-DR derivado de WT1 | |
| ES2331305T3 (es) | Peptidos de wt1 de tipo sustituido. | |
| AU2007298494B2 (en) | Antigen specific multi epitope vaccines | |
| ES2270870T3 (es) | Peptidos derivados de muc-1. | |
| ES2304398T3 (es) | Antigeno de tumores. | |
| ES2341785T3 (es) | Peptidos antigenicos del cancer derivados de wt1. | |
| CN101287831B (zh) | T细胞受体和编码该受体的核酸 | |
| KR102569204B1 (ko) | B형 간염 바이러스 감염에 대한 치료 백신접종을 위한 합성 롱 펩티드(slp) | |
| ES2328945T3 (es) | Epitopos inmunogenos de linfocitos t colaboradores de antigenos tumorales humanos y metodos inmunoterapeuticos utilizando dichos epitopos. | |
| JP2004154138A (ja) | 免疫原性ペプチド | |
| ES2373055T3 (es) | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. | |
| JP2002515868A (ja) | Ｈｌａ結合ペプチド及びその使用 | |
| US8946171B2 (en) | Immunization of an individual against carcinomas and the preliminary stages thereof | |
| JP2012529283A (ja) | 共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用 | |
| US8258261B2 (en) | Induction of tumor immunity by variants of folate binding protein | |
| TW201000119A (en) | MYBL2 epitope peptides and vaccines containing the same | |
| CN100467063C (zh) | 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用 | |
| ES2279257T3 (es) | Peptido del antigeno muc-1 para el desencadenamiento de una reaccion inmune frente a celulas tumorales. | |
| CA2634480C (en) | Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof | |
| ES2273670T3 (es) | Usos de polinucleotidos y polipeptidos casb618. | |
| WO2015005479A1 (ja) | 腫瘍抗原ペプチド | |
| JPWO2003037917A1 (ja) | 腫瘍抗原 | |
| JP2010530748A (ja) | プレプロカルシトニン抗原ｔエピトープ | |
| DK2891663T3 (en) | PSF1-Derived Peptide | |
| AU4047199A (en) | Tgfbeta rii receptor nucleic sequence, coded peptide, and uses |